JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma | Science




Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) …



Source link

About The Author

Scroll to Top